Go Pro
NASDAQ:CAMP

CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis

CAMP4 Therapeutics logo
$3.16 +0.15 (+4.98%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$3.23 +0.07 (+2.22%)
As of 07/24/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About CAMP4 Therapeutics Stock (NASDAQ:CAMP)

Advanced

Key Stats

Today's Range
$2.90
$3.20
50-Day Range
$3.01
$4.56
52-Week Range
$1.32
$7.75
Volume
169,623 shs
Average Volume
339,744 shs
Market Capitalization
$164.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.36
Consensus Rating
Moderate Buy

Company Overview

CAMP4 Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CAMP MarketRank™: 

CAMP4 Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 498th out of 836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CAMP4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 2 sell ratings.

  • Upside Potential

    CAMP4 Therapeutics has a consensus price target of $8.36, representing about 164.5% upside from its current price of $3.16.

  • Amount of Analyst Coverage

    CAMP4 Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about CAMP4 Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for CAMP4 Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CAMP4 Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CAMP4 Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CAMP4 Therapeutics has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.55% of the float of CAMP4 Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    CAMP4 Therapeutics has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in CAMP4 Therapeutics has recently increased by 9.98%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CAMP4 Therapeutics does not currently pay a dividend.

  • Dividend Growth

    CAMP4 Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    CAMP4 Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CAMP4 Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for CAMP on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CAMP4 Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.69% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    CAMP4 Therapeutics has minimal institutional ownership at this time.

  • Read more about CAMP4 Therapeutics' insider trading history.
Receive CAMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CAMP Stock News Headlines

CAMP4 Therapeutics Corporation
The comeback story of the century (ticker inside)
In 2013, this struggling PC maker went private amid skepticism from Forbes and the New York Times. Instead of fading, it transformed into what the Wall Street Journal called a globe-straddling AI supercomputer builder. The company has drawn attention from both Elon Musk and President Trump, who awarded it a five-year, 9.7 billion dollar Pentagon contract. Louis Navellier's system recently assigned it an A rating, the same grade given to Comfort Systems, Supermicro, and Applovin before their historic runs. Louis believes a major event on August 6 could bring new attention to this company's role in AI infrastructure.tc pixel
See More Headlines

CAMP Stock Analysis - Frequently Asked Questions

CAMP4 Therapeutics' stock was trading at $6.0850 at the beginning of 2026. Since then, CAMP shares have decreased by 48.1% and is now trading at $3.16.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) posted its quarterly earnings data on Thursday, May, 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.11. The Wireless communications provider had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative trailing twelve-month return on equity of 194.74%.

CAMP4 Therapeutics's stock reverse split before market open on Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

CAMP4 Therapeutics subsidiaries include LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and others.

CAMP4 Therapeutics (CAMP) raised $102 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 6,820,000 shares at a price of $14.00-$16.00 per share.

Shares of CAMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Zimmer Biomet (ZBH), Union Pacific (UNP), Charter Communications (CHTR), NVIDIA (NVDA), PayPal (PYPL), MercadoLibre (MELI) and Meta Platforms (META).

Company Calendar

Last Earnings
5/07/2026
Today
7/26/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Communications Equipment
Current Symbol
NASDAQ:CAMP
CIK
730255
Employees
644
Year Founded
1981

Price Target and Rating

High Price Target
$12.00
Low Price Target
$6.50
Potential Upside/Downside
+164.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$80.40 million
Net Margins
-2,193.72%
Pretax Margin
-2,193.72%
Return on Equity
-194.74%
Return on Assets
-95.64%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.15
Quick Ratio
6.15

Sales & Book Value

Annual Sales
$3.50 million
Price / Sales
46.89
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.02 per share
Price / Book
3.10

Miscellaneous

Outstanding Shares
51,930,000
Free Float
40,663,000
Market Cap
$164.10 million
Optionable
No Data
Beta
0.10

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:CAMP) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners